141 related articles for article (PubMed ID: 37470239)
1. Pharmacodynamics of rituximab in paediatric immune mediated diseases: B cell depletion and repopulation, effects on immunoglobulin levels and risk for infections.
Nassar-Sheikh Rashid A; Bergkamp SC; Kampinga RE; Gouw SC; Bouts AHM; Oosterveld MJS; Baars PA; van Leeuwen EMM; Kuijpers TW; van den Berg JM; Schonenberg-Meinema D
Clin Exp Rheumatol; 2023 Nov; 41(11):2323-2330. PubMed ID: 37470239
[TBL] [Abstract][Full Text] [Related]
2. Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases.
Oomen I; Nassar-Sheikh Rashid A; Bouts AHM; Gouw SC; Kuijpers TW; Rispens T; de Vries A; Wolbink G; van den Berg JM; Schonenberg-Meinema D
Clin Exp Rheumatol; 2022 Jan; 40(1):183-190. PubMed ID: 34251329
[TBL] [Abstract][Full Text] [Related]
3. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
[TBL] [Abstract][Full Text] [Related]
4. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
[TBL] [Abstract][Full Text] [Related]
5. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
6. Effect of different initial rituximab regimens on B cell depletion in children with autoimmune neurological diseases.
Zhang E; Wu Y; Chen C; Wei R; Zhang J; Xie H; Wei C; Ma L; Dong X; Li R; Zhou Y; Cui Y; Wu Y
Mult Scler Relat Disord; 2022 Mar; 59():103510. PubMed ID: 35114607
[TBL] [Abstract][Full Text] [Related]
7. Indications and Safety of Rituximab in Pediatric Neurology: A 10-Year Retrospective Study.
Nguyen AT; Cotteret C; Durrleman C; Barnerias C; Hully M; Gitiaux C; Mesples B; Bustamante J; Chhun S; Fayard C; Cisternino S; Treluyer JM; Desguerre I; Aubart M
Pediatr Neurol; 2022 Dec; 137():41-48. PubMed ID: 36228496
[TBL] [Abstract][Full Text] [Related]
8. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
Ebbo M; Grados A; Samson M; Groh M; Loundou A; Rigolet A; Terrier B; Guillaud C; Carra-Dallière C; Renou F; Pozdzik A; Labauge P; Palat S; Berthelot JM; Pennaforte JL; Wynckel A; Lebas C; Le Gouellec N; Quémeneur T; Dahan K; Carbonnel F; Leroux G; Perlat A; Mathian A; Cacoub P; Hachulla E; Costedoat-Chalumeau N; Harlé JR; Schleinitz N
PLoS One; 2017; 12(9):e0183844. PubMed ID: 28915275
[TBL] [Abstract][Full Text] [Related]
11. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease?
Deyà-Martínez A; Gordón Y; Molina-Anguita C; Vlagea A; Piquer M; Juan M; Esteve-Solé A; Antón J; Madrid Á; García-García A; Plaza AM; Armangue T; Alsina L
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32376706
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.
Kim SH; Park NY; Kim KH; Hyun JW; Kim HJ
Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35853752
[TBL] [Abstract][Full Text] [Related]
13. Safety of Obinutuzumab in Children With Autoimmune Encephalitis and Early B-Cell Repopulation on Rituximab.
Nguyen AT; Cotteret C; Gins C; Sarda E; Durrleman C; Mesples B; Bustamante J; Fayard C; Cisternino S; Desguerre I; Aubart M
Pediatr Neurol; 2024 Jul; 156():79-84. PubMed ID: 38733858
[TBL] [Abstract][Full Text] [Related]
14. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
15. B cell depletion for autoimmune diseases in paediatric patients.
Jansson AF; Sengler C; Kuemmerle-Deschner J; Gruhn B; Kranz AB; Lehmann H; Kleinert D; Pape L; Girschick HJ; Foeldvari I; Haffner D; Haas JP; Moebius D; Foell D; Peitz J; Grote V
Clin Rheumatol; 2011 Jan; 30(1):87-97. PubMed ID: 21120559
[TBL] [Abstract][Full Text] [Related]
16. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab.
de la Torre I; Leandro MJ; Edwards JC; Cambridge G
Clin Exp Rheumatol; 2012; 30(4):554-60. PubMed ID: 22510323
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study.
Padoan R; Felicetti M; Gatto M; Polito P; Doria A; Schiavon F
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):188-194. PubMed ID: 32441645
[TBL] [Abstract][Full Text] [Related]
18. B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study.
Nie Y; Li J; Wu D; Yang Y; Zhang L; Bai W; Jiang N; Qiao L; Huang C; Zhou S; Tian X; Li M; Zeng X; Peng L; Zhang W
Clin Exp Med; 2023 Dec; 23(8):4787-4795. PubMed ID: 37751119
[TBL] [Abstract][Full Text] [Related]
19. B-cell depletion induces prolonged remission in patients with giant cell hepatitis and autoimmune hemolytic anemia.
Matarazzo L; Di Chio T; Nastasio S; Tommasini A; Ventura A; Maggiore G
Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):66-72. PubMed ID: 31076361
[TBL] [Abstract][Full Text] [Related]
20. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
